NASDAQ:PASG Stock Quote
Passage Bio Inc is a biotechnology company focused on developing gene therapies for targeted genetic disorders
The company leverages its expertise in genetic medicine to create innovative treatments that address the root causes of diseases, with a particular emphasis on neurological conditions. By utilizing advanced vector technology and proprietary delivery systems, Passage Bio aims to provide transformative solutions that can improve patient outcomes and enhance the quality of life for individuals affected by these challenging health issues. The organization is committed to advancing its product pipeline through rigorous research and clinical development, seeking to bring groundbreaking therapies to market.
Frequently Asked Questions
How can investors learn more about Passage Bio, Inc.?
Investors can learn more about Passage Bio, Inc. by visiting the company’s official website, where they can find information about its clinical programs, press releases, financial reports, and investor presentations. The company also participates in investor conferences and provides updates through regulatory filings.
How does Passage Bio, Inc. approach research and development?
Passage Bio, Inc. adopts a rigorous research and development approach that includes preclinical and clinical studies designed to evaluate the safety and efficacy of its gene therapies. The company collaborates with academic institutions and industry partners to leverage the best scientific insights and accelerate drug development.
How does Passage Bio, Inc. engage with the patient community?
Passage Bio, Inc. engages with the patient community by prioritizing transparency, communication, and patient advocacy. The company collaborates with patient organizations to understand their needs better, gather insights, and ensure that the development of therapies aligns with patient expectations and experiences.
How does Passage Bio, Inc. ensure regulatory compliance?
Passage Bio, Inc. places great emphasis on regulatory compliance by adhering to the standards set by the U.S. Food and Drug Administration (FDA) and other regulatory bodies. The company maintains rigorous documentation practices and engages with regulatory officials throughout the drug development process.
Is Passage Bio, Inc. publicly traded?
Yes, Passage Bio, Inc. is publicly traded on the Nasdaq under the ticker symbol PASG. The company went public through an initial public offering (IPO) to raise capital for its research and development efforts, as well as to further its operational goals.
What are some of the diseases that Passage Bio, Inc. targets?
Passage Bio, Inc. focuses on rare neurological diseases, including conditions such as GM1 gangliosidosis and other genetic disorders that affect neurodegeneration and cognition. The company aims to provide solutions for these unmet medical needs through its gene therapy platforms.
What are the future goals of Passage Bio, Inc.?
The future goals of Passage Bio, Inc. include advancing its clinical programs through successful trial outcomes, expanding its therapy pipeline, and enhancing partnerships to accelerate the development of innovative treatments. The company is committed to fulfilling its mission of transforming patient lives through groundbreaking gene therapies.
What does Passage Bio, Inc. do?
Passage Bio, Inc. is a biotechnology company focused on developing innovative therapies for rare neurological diseases. The company specializes in gene therapies that harness the potential of adeno-associated virus (AAV) vectors to deliver genetic material directly to the central nervous system, aiming to address the underlying causes of debilitating conditions.
What financial strategies does Passage Bio, Inc. employ?
Passage Bio, Inc. employs a financial strategy that includes a combination of equity financing, collaborations, and grants to support its research and operational activities. The company is focused on maintaining a strong balance sheet to fund its innovative programs and clinical initiatives.
What is the importance of gene therapy in Passage Bio, Inc.'s mission?
Gene therapy is at the core of Passage Bio, Inc.'s mission as it offers a unique approach to addressing the genetic roots of rare neurological diseases. By introducing or altering genes to treat or prevent diseases, gene therapy holds the promise of providing lasting solutions that conventional therapies cannot achieve.
What is the mission of Passage Bio, Inc.?
The mission of Passage Bio, Inc. is to transform the lives of patients with rare neurological diseases by developing effective gene therapies that target the root causes of these conditions. The company is dedicated to scientific excellence, patient-focused research, and ensuring a sustainable development path for its therapeutics.
What is the organizational culture like at Passage Bio, Inc.?
The organizational culture at Passage Bio, Inc. is centered on innovation, collaboration, and a patient-first mindset. The company fosters an environment that encourages scientific inquiry and teamwork, recognizing the importance of diverse perspectives in driving research and achieving impactful outcomes.
What is the pipeline of Pipeline Bio, Inc.?
Passage Bio, Inc. has a diverse pipeline of gene therapy candidates aimed at treating various rare neurological conditions. The pipeline includes programs at different stages of development, from preclinical to clinical trials, with ongoing efforts to expand the therapeutic indications for its AAV-based technologies.
What is the status of Clinical Trials for Passage Bio, Inc.?
Passage Bio, Inc. is actively conducting clinical trials for its investigational therapies, focusing on assessing safety, efficacy, and dosage regimens for its pipeline candidates. These trials are a critical part of bringing innovative treatments from the lab to patients, and results are shared with the scientific community and regulatory agencies.
What is the technology behind Passage Bio, Inc.'s therapies?
The technology behind Passage Bio, Inc.'s therapies centers on adeno-associated virus (AAV) gene delivery systems. These systems allow for the safe and efficient delivery of therapeutic genes into the brain and central nervous system, providing a means to correct genetic deficiencies that lead to disease.
What partnerships does Passage Bio, Inc. have?
Passage Bio, Inc. has established partnerships with various academic institutions and biotechnology companies to enhance its research capabilities and expedite the development of its gene therapies. These collaborations facilitate knowledge sharing and access to state-of-the-art technologies.
When was Passage Bio, Inc. founded?
Passage Bio, Inc. was founded in 2019. The company's establishment was driven by a commitment to advancing gene therapies for patients suffering from rare neurological disorders, building on innovative science and deep industry expertise.
Where is Passage Bio, Inc. located?
Passage Bio, Inc. is headquartered in Philadelphia, Pennsylvania. The company benefits from its strategic location in a vibrant biotech hub, providing access to leading research institutions, talent, and collaborations within the life sciences sector.
Who are the key team members at Passage Bio, Inc.?
Passage Bio, Inc. is led by a team of experienced professionals with extensive backgrounds in biotechnology, pharmaceuticals, and gene therapy development. The leadership team includes experts in clinical development, regulatory affairs, and research, all committed to advancing the company’s mission.
What is the current price of Passage Bio, Inc. - Common Stock?
The current price of Passage Bio, Inc. - Common Stock is 0.4098
When was Passage Bio, Inc. - Common Stock last traded?
The last trade of Passage Bio, Inc. - Common Stock was at 2:11 pm EDT on April 2nd, 2025
What is the market capitalization of Passage Bio, Inc. - Common Stock?
The market capitalization of Passage Bio, Inc. - Common Stock is 25.31M
How many shares of Passage Bio, Inc. - Common Stock are outstanding?
Passage Bio, Inc. - Common Stock has 61.77M shares outstanding.